Letter to the Editor: The Hepa 1-6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy

Hepatology. 2024 Apr 1;79(4):E123-E124. doi: 10.1097/HEP.0000000000000733. Epub 2023 Dec 25.

Authors

Taicheng Lu^{1

2}, Jingzhi Zhang¹, Haiming Li¹, Guangda Li², Xiaohui Yin^{1

2}, Jingwen Yu³, Yingying Zheng¹, Zishen Liu¹, Yue Wang^{1

2}, Dong Chen¹, Yuancan Pan¹, Tongjing Ding¹, Yutong Zhang¹, Zhengzheng Yang¹, Zichun Yuan^{1

2}, Ganlin Zhang¹, Qingsheng Fan¹, Xiaomin Wang¹

Affiliations

¹ Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China.
² Graduate School, Beijing University of Chinese Medicine, Beijing, China.
³ Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

PMID: 38147319
DOI: 10.1097/HEP.0000000000000733

No abstract available

MeSH terms

Carcinoma, Hepatocellular* / drug therapy
Humans
Liver Neoplasms* / drug therapy